
Sutro Biopharma: Penny Stock Company Announces Cost Reduction Measures and Pipeline Refocusing
Sutro Biopharma’s Prioritization of Antibody-Drug Conjugates: A Game Changer in Cancer Therapy On Thursday, Sutro Biopharma, Inc. (STRO) made an important announcement regarding its focus on its antibody-drug conjugates (ADC) pipeline. The biotech company, based in South San Francisco, California, is prioritizing three wholly-owned preclinical programs in its next-generation ADC pipeline. What are Antibody-Drug Conjugates…